Developer docs
API playgroundTry for free, no card

Search company profiles

Core Diagnostics

Full company profile

uuid000312p

Namestring
Core Diagnostics
Legal namestring
Core Diagnostics Private Limited
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Core Diagnostics is a Gurugram-based Clinical Data Science company operating a high-end diagnostic laboratory platform in India. It serves oncologists, hematologists, gynecologists, cardiologists, and other specialists across 9 specialty areas (onCORE, hemaCORE, reproCORE, cardioCORE, endoCORE, nephroCORE, uroCORE, eyeCORE, neuroCORE) using molecular diagnostics, next-generation sequencing, liquid biopsy (52-gene liquiCORE panel), flow cytometry, immunohistochemistry (150+ markers via dualCORE), histopathology, cytogenetics, and telepathology. The company is CAP and NABL accredited, operates a hub-and-spoke network of one reference laboratory in Gurugram and six regional reference labs, and supports companion diagnostics for pharmaceutical companies.

The company monetizes through a hybrid model: one-time test fees across a premium menu (₹1,200–₹48,000 per test), subscription-based chronic disease management plans in partnership with CIPRA.ai (₹10,000–₹27,500), pharma clinical trial and companion diagnostic services, outsourced lab management for partner facilities, and the COREcertify professional education program. Distribution is omnichannel — direct B2C via website and call centre, B2B through hospitals and doctors, partner collection centres nationwide, and home collection services. Recent strategic moves include consolidation of its genomics lab into Metropolis Healthcare's Centre of Genomics (January 2026), an academic MoU with SRMIST (February 2026), and a multi-cancer screening collaboration with PredOmix (July 2023).

Short descriptiontext

Core Diagnostics is a Gurugram-based high-end clinical laboratory offering advanced molecular, genomic, and immunohistochemistry diagnostics across oncology, hematology, and chronic disease specialties, serving doctors, hospitals, pharma, and patients across India via seven labs and home collection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersGurugram, India
HQ citystring
Gurugram
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices17 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical diagnostic services, molecular diagnostics, next generation sequencing, immunohistochemistry panels, liquid biopsy testing
Industry4 codes
PRIMARYHLAFAMAJ
Reference & Esoteric Testing Laboratories
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Diagnostic Laboratory Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Clinical Laboratory Testing Services
TypeOne Time License
Description

One-time diagnostic test fees covering comprehensive panels across oncology, hematology, cardiology, nephrology, reproductive health, endocrinology, and neurology. Tests include molecular diagnostics, NGS panels, immunohistochemistry, flow cytometry, histopathology, cytopathology, and cytogenetics. Revenue recognized upon test completion and report delivery within 2-14 days.

corediagnostics.in
2Chronic Disease Subscription Plans
TypeSubscription Recurring
Description

Recurring subscription plans for AI-powered chronic disease management (Diabetes and Hypertension) combining CIPRA.ai app with periodic diagnostic monitoring tests. Plans offered as 6-month and 12-month subscriptions with bundled diagnostic tests at defined intervals.

corediagnostics.in
3Pharma Programs & Clinical Trial Services
TypeProfessional Services
Description

B2B revenue from pharma companies for clinical trial support, companion diagnostic development, and data services. The company positions itself as a bioinformatics partner for pharma's data-driven future in healthcare.

corediagnostics.in
4Lab Management Services
TypeManaged Services
Description

Outsourced lab management services where Core Diagnostics manages capital, skills, and management bandwidth for partner labs, focusing on patient care operations.

corediagnostics.in
5COREcertify Education Programs
TypeProfessional Services
Description

Professional education and certification programs for lab professionals covering latest testing methods and technologies in Histopathology, Immunohistochemistry, Cytology, Hematology & Molecular Genetics.

corediagnostics.in
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details19 tiers
16 Months Hypertension Management Plan
ModelSubscriptionBilling cadenceMonthly
Notes

₹10,000 for 6-month hypertension management subscription (7 months total plan). Includes AI-powered monitoring via CIPRA.ai and scheduled diagnostic tests.

corediagnostics.in
212 Months Hypertension Management Plan
ModelSubscriptionBilling cadenceAnnual
Notes

₹16,500 for 12-month subscription (14 months total with 1 month bonus). 30-day free trial included. Includes AI-powered monitoring via CIPRA.ai.

corediagnostics.in
36 Months Diabetes Management Plan
ModelSubscriptionBilling cadenceMonthly
Notes

₹16,000 for 6-month diabetes management and reversal subscription (7 months total plan). Includes HbA1c, Lipid Profile, AST, ALT, Microalbumin/Creatinine Ratio tests twice (once per quarter).

corediagnostics.in
412 Months Diabetes Management Plan
ModelSubscriptionBilling cadenceAnnual
Notes

₹27,500 for 12-month diabetes management and reversal subscription (14 months total with 1 month free trial). Includes HbA1c, Lipid Profile, AST, ALT (4 times/year), KFT, Thyroid Profile (once at start).

corediagnostics.in
5mammaCORE Panel 1
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹3,150 - Breast cancer panel covering ER, PR, HER2/neu biomarkers.

corediagnostics.in
6pulmoCORE 20 Gene Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹20,000 - Lung cancer panel covering hotspot SNVs/indels in 18 genes, gene fusions in 12 genes, and CNVs in 13 genes.

corediagnostics.in
7liquiCORE 52 Gene Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹48,000 - Comprehensive liquid biopsy panel covering 52 genes with SNVs, short indels, gene fusions, CNVs, and tumor suppressor genes.

corediagnostics.in
8liquiCORE Lung Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹35,000 - Lung cancer liquid biopsy panel covering hotspot SNVs, gene fusions, MET exon 14 skipping, and CNVs.

corediagnostics.in
9geneCORE Somatic 52 Gene Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹25,000 - Tissue-based somatic mutation panel for solid tumors covering 52 genes.

corediagnostics.in
10Comprehensive Hematological Malignancy Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹30,000 - Comprehensive hematological malignancy panel covering hotspot genes, full genes, gene fusions, and expression genes.

corediagnostics.in
11coloCORE Targeted Panel-1
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹22,000 - Colorectal cancer targeted panel covering TP53, KRAS, NRAS, BRAF, ERBB2, NTRK, PIK3CA, MSI-PCR.

corediagnostics.in
12coloCORE Targeted Panel-2
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹20,000 - Colorectal cancer targeted panel covering TP53, KRAS, NRAS, BRAF, ERBB2, NTRK, PIK3CA, MMR-IHC.

corediagnostics.in
13BRCA 1 and 2 Gene Sequencing Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Germline BRCA1 and BRCA2 gene sequencing for hereditary breast and ovarian cancer risk assessment.

corediagnostics.in
14Multiple Myeloma Diagnostic Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹10,500 - Multiple myeloma diagnostic panel covering Beta 2 Microglobulin, Immunoglobulins, Protein Electrophoresis, Immunofixation, Free Kappa/Lambda, KFT, LDH, Albumin, Calcium, CBC.

corediagnostics.in
15BCR-ABL Quantitative International Scale
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Quantitative BCR-ABL testing on International Scale for CML monitoring.

corediagnostics.in
16Pre Operative Profile
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹2,000 - Pre-surgical screening panel including CBC, Blood Group, Glucose, PT Studies, Electrolytes, Creatinine, HIV, HBsAg, HCV, APTT, Urine.

corediagnostics.in
17Women Infertility Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹2,649 - Infertility panel for women covering TSH, Prolactin, AMH.

corediagnostics.in
18Male Infertility Panel
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹1,699 - Infertility panel for men covering TSH, Testosterone Total, FSH, LH.

corediagnostics.in
19dualCORE (Upto 7 Markers)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

₹6,500 - IHC panel for carcinoma of unknown primary with up to 7 lineage-specific markers.

corediagnostics.in
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Core Diagnostics is a high-end clinical laboratory providing advanced molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, immunohistochemistry (IHC), flow cytometry, histopathology, cytogenetics, and companion diagnostic services across 9 specialty areas. The company delivers diagnostic test reports (turnaround 2-14 days) to referring physicians, hospitals, and directly to patients, while also offering B2B services including pharma clinical trial support and lab management for partner facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Illumina NovaSeq X Series infrastructure enables high-throughput, high-quality genomic sequencing at scale
+1 more record
Product overview1 text field

Core Diagnostics is a Clinical Data Science company with a Center-of-Excellence in High End Diagnostics, integrating Data Scientists, Lab Technicians, Pathologists, and AI Systems. The company operates a portfolio of nine CORE-branded diagnostic specialty panels: onCORE (hereditary and sporadic cancers), hemaCORE (hematological disorders), reproCORE (reproductive health), cardioCORE (cardiovascular diseases), endoCORE (endocrine disorders), nephroCORE (kidney diseases), uroCORE (urological disorders), eyeCORE (ophthalmologic conditions), and neuroCORE (brain and nervous system disorders). Complementing these, the company offers advanced targeted panels including dualCORE (150+ IHC markers for poorly differentiated tumors), liquiCORE (liquid biopsy panels for 52 genes and lung cancer), geneCORE Somatic, pulmoCORE, coloCORE, mammaCORE, and the Comprehensive Hematological Malignancy Panel. An integrated AI capability is provided through CIPRA.ai, a chronic disease management and reversal program using Digital Twin technology for personalized Diabetes and Hypertension care. Routine testing, subscription health plans, and home collection services round out the offering. The platform is supported by NABL and CAP accredited laboratories including a reference lab in Gurugram and six regional reference laboratories.

Product and service32 records
1onCORE
2hemaCORE
CategoryHematology Diagnostics
Description

Diagnostic solutions for multiple hematological disorders including leukemia, lymphoma, and myeloproliferative neoplasms, utilizing flow cytometry, molecular genetics, and cytogenetics. For hematologists and bone marrow transplant centers.

3reproCORE
CategoryReproductive Health Diagnostics
Description

Reproductive health diagnostic solutions encompassing infertility testing, prenatal screening, pregnancy monitoring, and sexual health diagnostics. For gynecologists, reproductive medicine specialists, and patients.

4cardioCORE
CategoryCardiology Diagnostics
Description

Genetic tests for cardiovascular diseases and non-invasive tests for heart blockage, supporting cardiac risk assessment and management. For cardiologists and patients with cardiac risk.

5endoCORE
CategoryEndocrinology Diagnostics
Description

Diagnosis of genetic endocrine disorders across a range of symptoms and severity levels, supporting endocrine disease stratification. For endocrinologists and patients.

6nephroCORE
CategoryNephrology Diagnostics
Description

Kidney disease diagnosis at an earlier stage than current diagnostic solutions, covering glomerular, tubular, and hereditary renal conditions. For nephrologists.

7uroCORE
CategoryUrology Diagnostics
Description

Detection of urological disorders affecting the urinary tract, bladder, and prostate through specialized molecular and histopathological testing. For urologists.

8eyeCORE
CategoryOphthalmology Diagnostics
Description

Specialized ophthalmologic testing for genetic and molecular eye disorders, supporting diagnosis of hereditary ocular conditions. For ophthalmologists.

9neuroCORE
CategoryNeurology Diagnostics
Description

Genetic testing and counselling for diagnosis of brain and nervous system disorders, covering neuro-oncology, neurodegenerative, and neurodevelopmental conditions. For neurologists.

10dualCORE
CategoryImmunohistochemistry Panel
Description

Advanced immunohistochemistry panel using esoteric lineage-specific and lineage-associated markers for the differential diagnostic work-up of poorly differentiated tumors, carcinomas of unknown primary, soft tissue sarcomas, hematolymphoid neoplasms, and neuroendocrine tumors. Features 150+ IHC markers. For oncologists and pathologists.

11liquiCORE 52 Gene Panel
CategoryLiquid Biopsy Panel
Description

Comprehensive liquid biopsy panel analyzing 52 genes for hotspot SNVs, short indels, gene fusions, copy number variations, and tumor suppressor genes across multiple cancer types from blood samples. For oncologists when tissue is unavailable.

12geneCORE Somatic 52 Gene Panel
CategorySomatic Mutation Panel
Description

Somatic gene panel covering 52 genes for hotspot mutations, gene fusions, and copy number variations to support oncology treatment selection and disease profiling in solid tumors. For oncologists.

13pulmoCORE 20 Gene Panel
CategoryLung Cancer Panel
Description

Pulmonary oncology panel targeting 20 genes for hotspot SNVs, gene fusions, and copy number variations in lung cancer, covering actionable targets including EGFR, ALK, ROS1, BRAF, KRAS, and NTRK. For pulmonologists and oncologists.

14coloCORE Targeted Panel-1
CategoryColorectal Cancer Panel
Description

Colorectal cancer targeted panel covering TP53, KRAS, NRAS, BRAF, ERBB2, NTRK1/2/3, PIK3CA with MSI-PCR testing for colorectal cancer molecular profiling. For oncologists.

15mammaCORE Panel 1
CategoryBreast Cancer Panel
Description

Breast cancer panel assessing ER, PR, and HER2/neu status for breast cancer diagnosis and treatment planning. For oncologists and breast surgeons.

16Comprehensive Hematological Malignancy Panel
CategoryHematological Malignancy Panel
Description

Broad hematology panel covering hotspot genes, full genes, gene fusions, and expression genes for comprehensive hematological malignancy profiling, including B-ALL MRD detection. For hematologists.

17BCR-ABL Quantitative International Scale
CategoryMolecular Monitoring Test
Description

Quantitative BCR-ABL molecular test on the International Scale for monitoring chronic myeloid leukemia treatment response and minimal residual disease. For hematologists.

18BRCA 1 and 2 Gene Sequencing Panel
CategoryHereditary Cancer Test
Description

Germline genetic testing panel for BRCA1 and BRCA2 gene sequencing to assess hereditary breast and ovarian cancer risk and guide PARP inhibitor therapy selection. For oncologists, genetic counselors, and patients.

19Multiple Myeloma Diagnostic Panel
CategoryMultiple Myeloma Panel
Description

Comprehensive diagnostic panel for multiple myeloma including serum protein electrophoresis, immunofixation, free light chains, beta-2 microglobulin, and routine chemistry for diagnosis and monitoring. For hematologists.

20Pre Operative Profile
CategoryPreoperative Test Panel
Description

Routine preoperative blood test panel covering CBC, blood group, glucose, kidney function, coagulation studies, and infectious disease screening (HIV, HBsAg, HCV) for surgical preparation. For surgeons and patients.

21Women Infertility Panel
CategoryFertility Test Panel
Description

Hormonal panel for female infertility assessment covering TSH, prolactin, and AMH for evaluation of ovarian reserve and reproductive health. For gynecologists and patients.

22Male Infertility Panel
CategoryFertility Test Panel
Description

Hormonal assessment panel for male infertility including testosterone total, FSH, and LH for evaluating male reproductive function. For andrologists and patients.

23Karyotyping for Genetic Disorders
CategoryCytogenetics Test
Description

Chromosomal karyotype analysis for detecting numerical and structural chromosomal abnormalities in genetic disorders, infertility, and prenatal cases. For geneticists and reproductive medicine specialists.

24Anti Nuclear Antibody (ANA/ANF) IFA
CategoryAutoimmune Test
Description

Immunofluorescence assay for antinuclear antibodies using HEp-2 cells as a screening test for autoimmune connective tissue diseases including SLE. For rheumatologists.

25Ph-like ALL Panel
CategoryLeukemia Panel
Description

Philadelphia chromosome-like acute lymphoblastic leukemia (BCR-ABL1-like ALL) diagnostic panel for high-risk subtype identification and tyrosine kinase inhibitor treatment decisions, recommended by NCCN. For hematologists.

26Histopathology Kidney Biopsy Panel (LM+IF)
CategoryHistopathology Panel
Description

Combined light microscopy and immunofluorescence analysis of kidney biopsy specimens for diagnosis of glomerular and renal parenchymal diseases. For nephropathologists and nephrologists.

27CIPRA Chronic Disease Management & Reversal Program
CategoryChronic Disease Management Program
Description

AI-powered chronic disease management subscription program in partnership with CIPRA.ai, utilizing Digital Twin technology to provide personalized, precise monitoring and lifestyle recommendations for Type 2 Diabetes and Hypertension management and reversal. Includes scheduled diagnostic monitoring tests. For chronic disease patients.

28Home Collection Service
CategorySample Collection Service
Description

At-home sample collection service with trained service executives using specialized collection kits, covering samples from doorstep to the main laboratory. Available across India including 12 countries. For patients preferring at-home sample collection.

29liquiCORE Lung Panel
CategoryLiquid Biopsy Panel
Description

Liquid biopsy panel targeting lung cancer-specific biomarkers including hotspot SNVs for ALK, BRAF, EGFR, KRAS, MET, NRAS, PIK3CA, ROS1, TP53, gene fusions, MET exon 14 skipping, and MET copy number variation. For oncologists managing lung cancer patients.

30ALL Multiplex Basic
CategoryLeukemia Panel
Description

Multiplex PCR panel for detecting key fusions in acute lymphoblastic leukemia including BCR-ABL, MLL-AF9, MLL-AF4, MLL-EN6, t(1;19), and t(12;21). For hematologists.

31B2B Lab Management Services
CategoryLab Management Service
Description

Outsourced lab management services where Core Diagnostics manages capital, skills, and management bandwidth for partner diagnostic labs, focusing on patient care operations and accreditation support. For partner diagnostic laboratories and hospital pathology departments.

32COREcertify Education Programs
CategoryProfessional Education
Description

Professional education and certification programs for lab professionals covering latest testing methods and technologies in Histopathology, Immunohistochemistry, Cytology, Hematology & Molecular Genetics. For lab professionals and pathologists.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

MoU signed to bridge academic learning and real-world oncology practice. Provides SRMIST students hands-on exposure to next-generation sequencing, genetic counselling frameworks, and industry-led research. Opens avenues for joint research initiatives aimed at advancing cancer diagnostics and improving patient outcomes.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-13
Description

Core Diagnostics' specialized genomics laboratory in Delhi NCR is integrated into Metropolis Healthcare's Centre of Genomics, which consolidates and scales capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research across India. The Centre unifies Metropolis's Global Reference Laboratory in Mumbai with Core Diagnostics' specialized genomics lab in Delhi NCR, operating as CAP-accredited national referral laboratories powered by Illumina NovaSeq X Series.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to launch AI-powered chronic disease management platform combining CIPRA.ai's AI digital twin technology with Core Diagnostics' periodic diagnostic monitoring tests for Diabetes and Hypertension management and reversal.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India- and US-based genomics and molecular diagnostics company focused on NGS-based hereditary and oncology testing. Most direct competitor to Core Diagnostics on liquid biopsy, NGS panels, and rare-disease genomics, serving similar oncologist and hospital segments.

TypeDirect peer
Description

Pan-India listed diagnostics chain with broad test menu including molecular diagnostics and genomics. Strategic partner that consolidated Core's genomics lab into its Centre of Genomics (Jan 2026), directly comparable on specialty testing, B2B hospital network, and accreditation standards.

TypeEmerging player
Description

US-based liquid biopsy specialist offering Guardant360 comprehensive genomic profiling; listed technology partner of Core Diagnostics. Comparable on liquid biopsy assays, oncology companion diagnostics, and pharma partnerships; global leader in circulating tumor DNA testing.

TypeBroad incumbent
Description

US-based molecular diagnostics leader (Roche subsidiary) specializing in comprehensive genomic profiling for oncology. Comparable to Core on liquid biopsy and comprehensive genomic panels; a benchmark for the global premium molecular diagnostics category Core aspires to compete in internationally.

TypeEmerging player
Description

India-based genomics and bioinformatics company focused on NGS, hereditary cancer testing, and clinical genomic interpretation. Closely comparable to Core's bioinformatics-driven specialty testing strategy, though smaller in consumer-facing scale.

TypeDirect peer
Description

Listed Indian diagnostic chain specializing in high-volume preventive and routine pathology. Comparable to Core on test-menu breadth and pan-India reach but operates at substantially lower price points and broader, less-specialized focus.

TypeBroad incumbent
Description

US-based molecular diagnostics and precision medicine company offering comprehensive tumor profiling (MI Profile), liquid biopsy, and AI-driven analytics. Comparable to Core Diagnostics on oncology molecular profiling and companion diagnostic development; substantially larger scale.

TypeDirect peer
Description

India-based multi-specialty diagnostic chain with strong presence in southern India and growing international footprint. Comparable to Core Diagnostics on advanced molecular testing, hospital partnerships, and integrated reference-lab model.

TypeDirect peer
Description

India's largest listed diagnostic chain by revenue and network, offering routine and specialized pathology nationwide. Comparable to Core Diagnostics on consumer testing, hospital B2B contracts, and NABL accreditation; differs through far greater scale and brand reach.

TypeDirect peer
Description

Major pan-India diagnostic chain with extensive specialty and reference lab capabilities, part of the Fortis/Manipal group. Comparable on hospital B2B pathology, oncology panels, and reference-lab accreditation; larger footprint and corporate backing distinguish it from Core.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Core Diagnostics

Clinical Diagnostic Laboratory Servicescorediagnostics.in

Core Diagnostics is a Gurugram-based high-end clinical laboratory offering advanced molecular, genomic, and immunohistochemistry diagnostics across oncology, hematology, and chronic disease specialties, serving doctors, hospitals, pharma, and patients across India via seven labs and home collection.

What Core Diagnostics does

Core Diagnostics is a Gurugram-based Clinical Data Science company operating a high-end diagnostic laboratory platform in India. It serves oncologists, hematologists, gynecologists, cardiologists, and other specialists across 9 specialty areas (onCORE, hemaCORE, reproCORE, cardioCORE, endoCORE, nephroCORE, uroCORE, eyeCORE, neuroCORE) using molecular diagnostics, next-generation sequencing, liquid biopsy (52-gene liquiCORE panel), flow cytometry, immunohistochemistry (150+ markers via dualCORE), histopathology, cytogenetics, and telepathology. The company is CAP and NABL accredited, operates a hub-and-spoke network of one reference laboratory in Gurugram and six regional reference labs, and supports companion diagnostics for pharmaceutical companies.

The company monetizes through a hybrid model: one-time test fees across a premium menu (₹1,200–₹48,000 per test), subscription-based chronic disease management plans in partnership with CIPRA.ai (₹10,000–₹27,500), pharma clinical trial and companion diagnostic services, outsourced lab management for partner facilities, and the COREcertify professional education program. Distribution is omnichannel — direct B2C via website and call centre, B2B through hospitals and doctors, partner collection centres nationwide, and home collection services. Recent strategic moves include consolidation of its genomics lab into Metropolis Healthcare's Centre of Genomics (January 2026), an academic MoU with SRMIST (February 2026), and a multi-cancer screening collaboration with PredOmix (July 2023).

Core Diagnostics firmographics

Firmographics
Name
Core Diagnostics
Legal name
Core Diagnostics Private Limited
Website
https://corediagnostics.in
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Core Diagnostics is a Gurugram-based high-end clinical laboratory offering advanced molecular, genomic, and immunohistochemistry diagnostics across oncology, hematology, and chronic disease specialties, serving doctors, hospitals, pharma, and patients across India via seven labs and home collection.
Ownership category
akta.pro rank

Core Diagnostics industry classification

Industry
Product category
Clinical Diagnostic Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAJ
Reference & Esoteric Testing Laboratories
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAL
Clinical Research & Trial Central Laboratories

Keywords

  • Clinical diagnostic services
  • Molecular diagnostics
  • Next generation sequencing
  • Immunohistochemistry panels
  • Liquid biopsy testing

Where Core Diagnostics is headquartered

Location

Headquarters

HQ city
Gurugram
HQ country
India
HQ region
Asia

Offices17 records

Markets served

Core Diagnostics business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Clinical Laboratory Testing Services: One-time diagnostic test fees covering comprehensive panels across oncology, hematology, cardiology, nephrology, reproductive health, endocrinology, and neurology. Tests include molecular diagnostics, NGS panels, immunohistochemistry, flow cytometry, histopathology, cytopathology, and cytogenetics. Revenue recognized upon test completion and report delivery within 2-14 days.
  2. Chronic Disease Subscription Plans: Recurring subscription plans for AI-powered chronic disease management (Diabetes and Hypertension) combining CIPRA.ai app with periodic diagnostic monitoring tests. Plans offered as 6-month and 12-month subscriptions with bundled diagnostic tests at defined intervals.
  3. Pharma Programs & Clinical Trial Services: B2B revenue from pharma companies for clinical trial support, companion diagnostic development, and data services. The company positions itself as a bioinformatics partner for pharma's data-driven future in healthcare.
  4. Lab Management Services: Outsourced lab management services where Core Diagnostics manages capital, skills, and management bandwidth for partner labs, focusing on patient care operations.
  5. COREcertify Education Programs: Professional education and certification programs for lab professionals covering latest testing methods and technologies in Histopathology, Immunohistochemistry, Cytology, Hematology & Molecular Genetics.

Pricing tiers

ModelBillingPrice
SubscriptionMonthly6 Months Hypertension Management Plan
SubscriptionAnnual12 Months Hypertension Management Plan
SubscriptionMonthly6 Months Diabetes Management Plan
SubscriptionAnnual12 Months Diabetes Management Plan
Unit PricingPay-as-you-gomammaCORE Panel 1
Unit PricingPay-as-you-gopulmoCORE 20 Gene Panel
Unit PricingPay-as-you-goliquiCORE 52 Gene Panel
Unit PricingPay-as-you-goliquiCORE Lung Panel
Unit PricingPay-as-you-gogeneCORE Somatic 52 Gene Panel
Unit PricingPay-as-you-goComprehensive Hematological Malignancy Panel
Unit PricingPay-as-you-gocoloCORE Targeted Panel-1
Unit PricingPay-as-you-gocoloCORE Targeted Panel-2
Unit PricingPay-as-you-goBRCA 1 and 2 Gene Sequencing Panel
Unit PricingPay-as-you-goMultiple Myeloma Diagnostic Panel
Unit PricingPay-as-you-goBCR-ABL Quantitative International Scale
Unit PricingPay-as-you-goPre Operative Profile
Unit PricingPay-as-you-goWomen Infertility Panel
Unit PricingPay-as-you-goMale Infertility Panel
Unit PricingPay-as-you-godualCORE (Upto 7 Markers)

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core Diagnostics product offering

Product offering

Core offering

Core Diagnostics is a high-end clinical laboratory providing advanced molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, immunohistochemistry (IHC), flow cytometry, histopathology, cytogenetics, and companion diagnostic services across 9 specialty areas. The company delivers diagnostic test reports (turnaround 2-14 days) to referring physicians, hospitals, and directly to patients, while also offering B2B services including pharma clinical trial support and lab management for partner facilities.

Product overview

Core Diagnostics is a Clinical Data Science company with a Center-of-Excellence in High End Diagnostics, integrating Data Scientists, Lab Technicians, Pathologists, and AI Systems. The company operates a portfolio of nine CORE-branded diagnostic specialty panels: onCORE (hereditary and sporadic cancers), hemaCORE (hematological disorders), reproCORE (reproductive health), cardioCORE (cardiovascular diseases), endoCORE (endocrine disorders), nephroCORE (kidney diseases), uroCORE (urological disorders), eyeCORE (ophthalmologic conditions), and neuroCORE (brain and nervous system disorders). Complementing these, the company offers advanced targeted panels including dualCORE (150+ IHC markers for poorly differentiated tumors), liquiCORE (liquid biopsy panels for 52 genes and lung cancer), geneCORE Somatic, pulmoCORE, coloCORE, mammaCORE, and the Comprehensive Hematological Malignancy Panel. An integrated AI capability is provided through CIPRA.ai, a chronic disease management and reversal program using Digital Twin technology for personalized Diabetes and Hypertension care. Routine testing, subscription health plans, and home collection services round out the offering. The platform is supported by NABL and CAP accredited laboratories including a reference lab in Gurugram and six regional reference laboratories.

Differentiator

Problem solved

Functional benefit

Products and services

  • onCORE
  • hemaCORE Diagnostic solutions for multiple hematological disorders including leukemia, lymphoma, and myeloproliferative neoplasms, utilizing flow cytometry, molecular genetics, and cytogenetics. For hematologists and bone marrow transplant centers.
  • reproCORE Reproductive health diagnostic solutions encompassing infertility testing, prenatal screening, pregnancy monitoring, and sexual health diagnostics. For gynecologists, reproductive medicine specialists, and patients.
  • cardioCORE Genetic tests for cardiovascular diseases and non-invasive tests for heart blockage, supporting cardiac risk assessment and management. For cardiologists and patients with cardiac risk.
  • endoCORE Diagnosis of genetic endocrine disorders across a range of symptoms and severity levels, supporting endocrine disease stratification. For endocrinologists and patients.
  • nephroCORE Kidney disease diagnosis at an earlier stage than current diagnostic solutions, covering glomerular, tubular, and hereditary renal conditions. For nephrologists.
  • uroCORE Detection of urological disorders affecting the urinary tract, bladder, and prostate through specialized molecular and histopathological testing. For urologists.
  • eyeCORE Specialized ophthalmologic testing for genetic and molecular eye disorders, supporting diagnosis of hereditary ocular conditions. For ophthalmologists.
  • neuroCORE Genetic testing and counselling for diagnosis of brain and nervous system disorders, covering neuro-oncology, neurodegenerative, and neurodevelopmental conditions. For neurologists.
  • dualCORE Advanced immunohistochemistry panel using esoteric lineage-specific and lineage-associated markers for the differential diagnostic work-up of poorly differentiated tumors, carcinomas of unknown primary, soft tissue sarcomas, hematolymphoid neoplasms, and neuroendocrine tumors. Features 150+ IHC markers. For oncologists and pathologists.
  • liquiCORE 52 Gene Panel Comprehensive liquid biopsy panel analyzing 52 genes for hotspot SNVs, short indels, gene fusions, copy number variations, and tumor suppressor genes across multiple cancer types from blood samples. For oncologists when tissue is unavailable.
  • geneCORE Somatic 52 Gene Panel Somatic gene panel covering 52 genes for hotspot mutations, gene fusions, and copy number variations to support oncology treatment selection and disease profiling in solid tumors. For oncologists.
  • pulmoCORE 20 Gene Panel Pulmonary oncology panel targeting 20 genes for hotspot SNVs, gene fusions, and copy number variations in lung cancer, covering actionable targets including EGFR, ALK, ROS1, BRAF, KRAS, and NTRK. For pulmonologists and oncologists.
  • coloCORE Targeted Panel-1 Colorectal cancer targeted panel covering TP53, KRAS, NRAS, BRAF, ERBB2, NTRK1/2/3, PIK3CA with MSI-PCR testing for colorectal cancer molecular profiling. For oncologists.
  • mammaCORE Panel 1 Breast cancer panel assessing ER, PR, and HER2/neu status for breast cancer diagnosis and treatment planning. For oncologists and breast surgeons.
  • Comprehensive Hematological Malignancy Panel Broad hematology panel covering hotspot genes, full genes, gene fusions, and expression genes for comprehensive hematological malignancy profiling, including B-ALL MRD detection. For hematologists.
  • BCR-ABL Quantitative International Scale Quantitative BCR-ABL molecular test on the International Scale for monitoring chronic myeloid leukemia treatment response and minimal residual disease. For hematologists.
  • BRCA 1 and 2 Gene Sequencing Panel Germline genetic testing panel for BRCA1 and BRCA2 gene sequencing to assess hereditary breast and ovarian cancer risk and guide PARP inhibitor therapy selection. For oncologists, genetic counselors, and patients.
  • Multiple Myeloma Diagnostic Panel Comprehensive diagnostic panel for multiple myeloma including serum protein electrophoresis, immunofixation, free light chains, beta-2 microglobulin, and routine chemistry for diagnosis and monitoring. For hematologists.
  • Pre Operative Profile Routine preoperative blood test panel covering CBC, blood group, glucose, kidney function, coagulation studies, and infectious disease screening (HIV, HBsAg, HCV) for surgical preparation. For surgeons and patients.
  • Women Infertility Panel Hormonal panel for female infertility assessment covering TSH, prolactin, and AMH for evaluation of ovarian reserve and reproductive health. For gynecologists and patients.
  • Male Infertility Panel Hormonal assessment panel for male infertility including testosterone total, FSH, and LH for evaluating male reproductive function. For andrologists and patients.
  • Karyotyping for Genetic Disorders Chromosomal karyotype analysis for detecting numerical and structural chromosomal abnormalities in genetic disorders, infertility, and prenatal cases. For geneticists and reproductive medicine specialists.
  • Anti Nuclear Antibody (ANA/ANF) IFA Immunofluorescence assay for antinuclear antibodies using HEp-2 cells as a screening test for autoimmune connective tissue diseases including SLE. For rheumatologists.
  • Ph-like ALL Panel Philadelphia chromosome-like acute lymphoblastic leukemia (BCR-ABL1-like ALL) diagnostic panel for high-risk subtype identification and tyrosine kinase inhibitor treatment decisions, recommended by NCCN. For hematologists.
  • Histopathology Kidney Biopsy Panel (LM+IF) Combined light microscopy and immunofluorescence analysis of kidney biopsy specimens for diagnosis of glomerular and renal parenchymal diseases. For nephropathologists and nephrologists.
  • CIPRA Chronic Disease Management & Reversal Program AI-powered chronic disease management subscription program in partnership with CIPRA.ai, utilizing Digital Twin technology to provide personalized, precise monitoring and lifestyle recommendations for Type 2 Diabetes and Hypertension management and reversal. Includes scheduled diagnostic monitoring tests. For chronic disease patients.
  • Home Collection Service At-home sample collection service with trained service executives using specialized collection kits, covering samples from doorstep to the main laboratory. Available across India including 12 countries. For patients preferring at-home sample collection.
  • liquiCORE Lung Panel Liquid biopsy panel targeting lung cancer-specific biomarkers including hotspot SNVs for ALK, BRAF, EGFR, KRAS, MET, NRAS, PIK3CA, ROS1, TP53, gene fusions, MET exon 14 skipping, and MET copy number variation. For oncologists managing lung cancer patients.
  • ALL Multiplex Basic Multiplex PCR panel for detecting key fusions in acute lymphoblastic leukemia including BCR-ABL, MLL-AF9, MLL-AF4, MLL-EN6, t(1;19), and t(12;21). For hematologists.
  • B2B Lab Management Services Outsourced lab management services where Core Diagnostics manages capital, skills, and management bandwidth for partner diagnostic labs, focusing on patient care operations and accreditation support. For partner diagnostic laboratories and hospital pathology departments.
  • COREcertify Education Programs Professional education and certification programs for lab professionals covering latest testing methods and technologies in Histopathology, Immunohistochemistry, Cytology, Hematology & Molecular Genetics. For lab professionals and pathologists.

Quantifiable outcome

  • Illumina NovaSeq X Series infrastructure enables high-throughput, high-quality genomic sequencing at scale
  • +1 more outcomes

Companies that use Core Diagnostics

Customer profile

Named customers6 records

Segments7 records

Ideal customer profiles4 records

Core Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature9 records

Core Diagnostics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • SRM Institute of Science and Technology (SRMIST)coreStrategic or Co-development Partner · 23 February 2026MoU signed to bridge academic learning and real-world oncology practice. Provides SRMIST students hands-on exposure to next-generation sequencing, genetic counselling frameworks, and industry-led research. Opens avenues for joint research initiatives aimed at advancing cancer diagnostics and improving patient outcomes.
  • Metropolis HealthcareflagshipStrategic or Co-development Partner · 13 January 2026Core Diagnostics' specialized genomics laboratory in Delhi NCR is integrated into Metropolis Healthcare's Centre of Genomics, which consolidates and scales capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research across India. The Centre unifies Metropolis's Global Reference Laboratory in Mumbai with Core Diagnostics' specialized genomics lab in Delhi NCR, operating as CAP-accredited national referral laboratories powered by Illumina NovaSeq X Series.
  • CIPRA.aicoreStrategic or Co-development PartnerPartnership to launch AI-powered chronic disease management platform combining CIPRA.ai's AI digital twin technology with Core Diagnostics' periodic diagnostic monitoring tests for Diabetes and Hypertension management and reversal.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Core Diagnostics competitors and assessment

Company assessment

Direct peers

  • MedGenome: India- and US-based genomics and molecular diagnostics company focused on NGS-based hereditary and oncology testing. Most direct competitor to Core Diagnostics on liquid biopsy, NGS panels, and rare-disease genomics, serving similar oncologist and hospital segments.
  • Metropolis Healthcare: Pan-India listed diagnostics chain with broad test menu including molecular diagnostics and genomics. Strategic partner that consolidated Core's genomics lab into its Centre of Genomics (Jan 2026), directly comparable on specialty testing, B2B hospital network, and accreditation standards.
  • Thyrocare Technologies: Listed Indian diagnostic chain specializing in high-volume preventive and routine pathology. Comparable to Core on test-menu breadth and pan-India reach but operates at substantially lower price points and broader, less-specialized focus.
  • Neuberg Diagnostics: India-based multi-specialty diagnostic chain with strong presence in southern India and growing international footprint. Comparable to Core Diagnostics on advanced molecular testing, hospital partnerships, and integrated reference-lab model.
  • Dr. Lal PathLabs: India's largest listed diagnostic chain by revenue and network, offering routine and specialized pathology nationwide. Comparable to Core Diagnostics on consumer testing, hospital B2B contracts, and NABL accreditation; differs through far greater scale and brand reach.
  • Agilus Diagnostics (formerly SRL Diagnostics): Major pan-India diagnostic chain with extensive specialty and reference lab capabilities, part of the Fortis/Manipal group. Comparable on hospital B2B pathology, oncology panels, and reference-lab accreditation; larger footprint and corporate backing distinguish it from Core.

Emerging players

  • Guardant Health: US-based liquid biopsy specialist offering Guardant360 comprehensive genomic profiling; listed technology partner of Core Diagnostics. Comparable on liquid biopsy assays, oncology companion diagnostics, and pharma partnerships; global leader in circulating tumor DNA testing.
  • Strand Life Sciences: India-based genomics and bioinformatics company focused on NGS, hereditary cancer testing, and clinical genomic interpretation. Closely comparable to Core's bioinformatics-driven specialty testing strategy, though smaller in consumer-facing scale.

Broad incumbents

  • Foundation Medicine: US-based molecular diagnostics leader (Roche subsidiary) specializing in comprehensive genomic profiling for oncology. Comparable to Core on liquid biopsy and comprehensive genomic panels; a benchmark for the global premium molecular diagnostics category Core aspires to compete in internationally.
  • Caris Life Sciences: US-based molecular diagnostics and precision medicine company offering comprehensive tumor profiling (MI Profile), liquid biopsy, and AI-driven analytics. Comparable to Core Diagnostics on oncology molecular profiling and companion diagnostic development; substantially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Core Diagnostics social profiles

Digital presence

Core Diagnostics compliance and trust

Trust signal

Compliance2 records

Core Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Core Diagnostics leadership team

Management profile

Number of profiles

Profiles5 records

Core Diagnostics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Core Diagnostics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Core Diagnostics

What does Core Diagnostics do?

Core Diagnostics is a high-end clinical laboratory providing advanced molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, immunohistochemistry (IHC), flow cytometry, histopathology, cytogenetics, and companion diagnostic services across 9 specialty areas. The company delivers diagnostic test reports (turnaround 2-14 days) to referring physicians, hospitals, and directly to patients, while also offering B2B services including pharma clinical trial support and lab management for partner facilities.

Is Core Diagnostics a public or private company?

Core Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Core Diagnostics founded?

Core Diagnostics was founded in 2012. It employs 501 to 1,000 people.

Where is Core Diagnostics based?

Core Diagnostics is headquartered in Gurugram, India, in the Asia region.

How does Core Diagnostics make money?

Five revenue lines are on record. Clinical Laboratory Testing Services are the primary driver. The others are chronic Disease Subscription Plans, pharma Programs & Clinical Trial Services, lab Management Services and COREcertify Education Programs.

Who are Core Diagnostics's main competitors?

Direct peers on record are MedGenome, Metropolis Healthcare, Thyrocare Technologies, Neuberg Diagnostics, Dr. Lal PathLabs and Agilus Diagnostics (formerly SRL Diagnostics). Emerging players are Guardant Health and Strand Life Sciences. Broad incumbents are Foundation Medicine and Caris Life Sciences.

Does Core Diagnostics have an API?

No public API is recorded for Core Diagnostics.

What industry is Core Diagnostics in?

Core Diagnostics's product category is Clinical Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAFAMAJ, Reference & Esoteric Testing Laboratories, with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEarnings call transcript: Metropolis Healthcare Q1 2026 beats estimates By Investing.comMetropolis Healthcare Limited reported a Q1 2026 earnings beat with revenue of INR 450 crores (up 17% year-over-year) and EBITDA of INR 113 crores (up 27% YoY), driven by double-digit volume growth in both patient volumes (10%) and test volumes (11%) without any price increases. The company maintained its FY 2027 revenue growth outlook of 14%-16% and expects EBITDA margin expansion of 100-150 basis points, targeting 27%-28% margins over the current and next year. Management highlighted broad-based growth across B2C (up 18%) and B2B (up 15%) channels, with North India emerging as the fastest-growing region at 19% growth, contributing 18% of total revenue following the Core Diagnostics acquisition.Medical BuyerPrecision oncology creating new opportunities for Indian healthcare firmsPrecision oncology is creating strategic opportunities for Indian healthcare companies as treatment shifts from organ-based to genetics-based approaches, driven by rising cancer cases in India (projected to reach 25 lakh annually by 2045) and declining genome sequencing costs. Metropolis Healthcare acquired Core Diagnostics in December 2024 for ₹246.8 crore, raising its oncology revenue share from 4% to approximately 10% and achieving a financial turnaround with EBITDA margins reaching high single-digits by Q4 FY26, while FY26 group revenue grew 24% year-on-year to ₹1,646 crore. Syngene International, which works with 16 of the world's top 20 pharmaceutical companies including a partnership with Bristol Myers Squibb extended through 2035, is expanding into antibody-drug conjugates and biologics, though its stock has corrected 30% due to temporary inventory normalization affecting EBITDA margins.Towards HealthcareCore Clinical Molecular Diagnostics Market Size, Trends and Shares by 2034The core clinical molecular diagnostics market is projected to grow from $5.3 billion in 2023 to $14.45 billion by 2034, a CAGR of 9.54%. North America led in 2023, while Asia-Pacific is expected to grow fastest. The reagents segment dominated, with PCR as the leading technique.India's most comprehensive portal on pharmaceutical NewsSRMIST and CORE Diagnostics partner to strengthen future-ready talent in oncology and genetic diagnosticsSRM Institute of Science and Technology (SRMIST) has signed a Memorandum of Understanding with CORE Diagnostics, a global cancer diagnostics and genomic testing company, to bridge the gap between academic learning and real-world oncology practice. The partnership will provide SRMIST students with hands-on exposure to next-generation sequencing, genetic counselling frameworks, and industry-led research, while also opening avenues for joint research initiatives aimed at advancing cancer diagnostics and improving patient outcomes.AETOSWireQritive Secures Multi-Year Contracts with Metropolis Healthcare, CŌRE Diagnostics and Rajiv Gandhi Cancer Institute to Drive AI Adoption in Pathology Across IndiaQritive secured multi-year contracts with Metropolis Healthcare, CŌRE Diagnostics, and Rajiv Gandhi Cancer Institute to integrate its AI pathology platform. The company claims its AI modules enable up to 90% faster diagnoses and 80% less discordance. The partnerships aim to improve diagnostic precision and patient outcomes across India.Business TodayBehind the goldrush to bring DNA testing to IndiaIndia's genomic testing industry is experiencing rapid growth, driven by surging demand across oncology, rare diseases, reproductive genomics and preventive health, with the country's DNA sequencing market valued at $270 million in 2023 and projected to reach $1.4 billion by 2030 at a 27% CAGR. Hospital chains, diagnostics networks and investors have poured hundreds of millions into sequencing infrastructure, with major acquisitions reshaping the fragmented pathology market, valued at $8 billion and home to over 150,000 labs. Despite challenges including test costs ranging from ₹20,000 to ₹1 lakh, limited insurance coverage, and regulatory uncertainties, industry leaders project that genomics will become embedded across India's mainstream clinical care by 2030, potentially transforming the country from a consumer of global genomic solutions to a creator.YahooCancer Diagnostics Market Outlook, Forecast Trends and Growth Report 2025-2034 | Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling GrowthThe global cancer diagnostics market was valued at USD 23.84 billion in 2024 and is forecast to reach USD 70.80 billion by 2034, growing at an 11.5% CAGR. Growth is driven by rising cancer cases, early detection initiatives, and technologies like liquid biopsies and AI. Specific deals include Metropolis Healthcare's acquisition of Core Diagnostics for USD 29.62 million and ARC Innovation's USD 5.1 million funding for Starget Pharma.GlobeNewswireCancer Diagnostics Market Outlook, Forecast Trends and Growth Report 2025-2034 | Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling GrowthThe global cancer diagnostics market was valued at USD 23.84 billion in 2024 and is forecast to grow at an 11.5% CAGR to reach USD 70.80 billion by 2034. Growth is driven by rising cancer cases, early detection initiatives, and technologies like liquid biopsies and AI. Specific deals include Metropolis Healthcare's acquisition of Core Diagnostics for USD 29.62 million and ARC Innovation's USD 5.1 million funding for Starget Pharma.LinkedInDecoding M&A in India’s Diagnostics Sector: What Acquirers Are Really Looking ForIndia's diagnostics sector is experiencing significant consolidation driven by rising healthcare awareness and demand for quality labs in Tier 2 and Tier 3 cities, with strategic and financial buyers actively acquiring regional chains to build national platforms. Key transactions include Metropolis Healthcare's acquisitions of Core Diagnostics (₹246.8 crore) and Hitech Diagnostic Centre (₹636 crore), PharmEasy's acquisition of a 66.1% stake in Thyrocare Technologies (₹4,546 crore), and Dr. Lal PathLabs' purchase of Suburban Diagnostics (₹925 crore). The article analyzes three critical acquirer considerations: margin accretion through operational synergies, target attractiveness criteria including revenue size and business model, and post-COVID valuation normalization.